Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases

Fuller, Amy, Hancox, Jennie, Williams, Hywel C., Card, Tim, Taal, Maarten W., Aithal, Guruprasad P., Fox, Christopher P., Mallen, Christian D., Maxwell, James R., Bingham, Sarah, Vedhara, Kavita and Abhishek, Abhishek 2024. Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases. Rheumatology , keae175. 10.1093/rheumatology/keae175

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution. Download (420kB) | Preview

Abstract

Objective: To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s). Methods: Adults (≥18 years) taking immune-suppressing treatment(s) for at-least six months, and healthcare professionals (HCPs) with experience of either prescribing and/or monitoring immune-suppressing drugs were invited to participate in a single, remote, one-to-one, semi-structured interview. Interviews were conducted by a trained qualitative researcher and explored their views and experiences of current monitoring and acceptability of a proposed risk-stratified monitoring plan. Interviews were transcribed verbatim and inductively analysed using thematic analysis in NVivo. Results: Eighteen patients and 13 HCPs were interviewed. While participants found monitoring of immune-suppressing drugs with frequent blood-tests reassuring, the current frequency of these was considered burdensome by patients and HCPs alike, and to be a superfluous use of healthcare resources. Given abnormalities rarely arose during long-term treatment, most felt that monitoring blood-tests were not needed as often. Patients and HCPs found it acceptable to increase the interval between monitoring blood-tests from three-monthly to six-monthly or annually depending on the patients’ risk profiles. Conditions of accepting such a change included: allowing for clinician and patient autonomy in determining an individuals’ frequency of monitoring blood-tests, the flexibility to change monitoring frequency if someone’s risk profile changed, and endorsement from specialist societies and healthcare providers such as the National Health Service. Conclusion: A risk-stratified approach to monitoring was acceptable to patients and HCPs. Guideline groups should consider these findings when recommending blood-test monitoring intervals.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Psychology
Publisher:	Oxford University Press
ISSN:	1462-0324
Funders:	National Institute for Health and Care Research - Health Technology Assessment grant (NIHR130580)
Date of First Compliant Deposit:	18 March 2024
Date of Acceptance:	12 March 2024
Last Modified:	04 Apr 2024 10:12
URI:	https://orca.cardiff.ac.uk/id/eprint/167316

Actions (repository staff only)

Edit Item